Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
-
J Oncol Pharm Pract · Aug 2020
Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
Prostate cancer is the second leading cause of cancer death in men. Androgen deprivation therapy (ADT) has been the primary therapeutic approach for treatment of prostate cancer. However,nearly all patients develop the castration-resistant disease . We evaluated real-world data with abiraterone and enzalutamide treatment. By this data, we aimed to analyze whether that prior short response to ADT could predict response to subsequent therapy with androgen receptor axis targeted agent (ARATA). ⋯ TTCR is also a predictor for PFS of the patients who were treated ARATA both whole cohort and post-docetaxel.